BioSpace News Archive

Rheos Medicines today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S. to its board of directors.

Scopus BioPharma Inc. today announced a new management appointment following its acquisition of Olimmune Inc.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir, an investigational oral antiviral therapeutic.

Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea together with other members of the Atea management team, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 p.m. ET.

Renovacor, Inc., an early‑stage biotechnology company developing adeno-associated virus ‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regulatory affairs and quality assurance.

Clinical Laserthermia Systems AB today announced it has received approval from Health Canada for its updated sterilization documentation as well as an acceptance for its new sterilization supplier, ROSE GmbH.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of the health economic model for OLINVYK injection in Journal of Comparative Effectiveness Research.

SPI Pharma introduces UltraBurst™, providing a step-change in the most critical orally disintegrating tablet characteristics — dissolution time.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the publication of retrospective data evaluating fusion rates in patients receiving three- and four-level lumbar arthrodesis surgery who were treated adjunctively with the SpinalStim™ bone growth therapy device.

VectivBio Holding AG today announced it has nominated Paul R. Carter and Murray W. Stewart, DM, FRCP, for election as Independent Non-Executive Directors on its Board of Directors.